Maulik Nanavaty

Maulik Nanavaty, CEO of Anumana

Maulik Nanavaty is the newly appointed Chief Executive Officer and member of the Board of Directors at Anumana, an AI-driven health technology company.1234 He will lead Anumana through a period of growth as the company begins deploying and commercializing its multi-indication ECG-AI platform technology.14

Prior to joining Anumana, Nanavaty spent 18 years at Boston Scientific, where he served as a senior executive with extensive commercial and operational medical device experience in the U.S. and international markets.123 Most recently, he was senior vice president and president of Neuromodulation at Boston Scientific, leading the development and commercialization of microelectronic implantable technologies and software used to treat neurological diseases and other chronic conditions.123

Before that, Nanavaty served as president of Boston Scientific Japan, and previously vice president and general manager of Interventional Cardiology, Boston Scientific Japan.123 Prior to Boston Scientific, he spent 16 years in various executive positions at Baxter International.13

Nanavaty joins Anumana after the company's recent FDA clearance of its breakthrough ECG-AI LEF device for detecting low ejection fraction, a common undiagnosed indicator of heart failure.12 Anumana's ECG-AI platform represents a breakthrough approach to ECG interpretation, enabling identification of hidden cardiovascular diseases from standard ECGs at the point of care.12

In addition to his role as CEO of Anumana, Nanavaty joins nference as president, Ventures.12 He will continue to serve as a board member of Rani Therapeutics, a publicly listed biotherapeutics company.1